|
| Study | Number of patients | Therapy | Results | Conclusions |
|
| Jiang et al., 2006 [21] | 57 | Gastrectomy and chemotherapy; immunotherapy group: additional CIK infusions | Better survival rate of patients in immunotherapy group only in beginning—after 2 yrs no difference in survival between the groups | Combination of chemo- and CIK cell therapy superior to chemotherapy alone in patients with advanced gastric cancer |
|
| Shi et al., 2012 [22] | 151 | Gastrectomy and chemotherapy; immunotherapy group: additional CIK cell therapy | The mean CD3+, CD4+ level and the CD4+/CD8+ ratio increased in patients’ blood up to 2 months after immunotherapy; no severe side effects; OS and DFS significantly better in immunotherapy group | CIK cell therapy can prolong DFS and OS; patients with intestinal-type tumors benefit most from CIK cell therapy as determined by retrospective subgroup analysis |
|
| Wang et al., 2013 [23] | 42 | Chemotherapy; immunotherapy group: additional i.p. perfusion of CIK cells | Reduced volume of 2-cycle peritoneal fluid drainage in immunotherapy group; no serious adverse reactions; prolonged TTP and higher OS in immunotherapy group | Superior efficacy of combination of chemo- and CIK cell therapy for advanced gastric cancer patients with ascites; CIK cell therapy can enhance immunological function and prolong survival |
|
| Jiang et al., 2008 [24] | 60 | Chemotherapy; immunotherapy group: additional CIK cell transfusions | The remission rate was 58.6% in the immunotherapy group and 45.2% in the control group; side effects of CIK cell transfusions were chills, fever, general malaise, nausea, and vomiting | CIK cell therapy can reduce clinical signs of elderly advanced gastric cancer patients; side effects can be treated with conventional therapy |
|
| Jiang et al., 2010 [25] | 156 | Chemotherapy; immunotherapy group: additional CIK cell therapy | Significantly longer 2- and 5-yr survival time | Better survival after CIK cell therapy; increasing the frequency of CIK cell therapy seems to be beneficial for survival |
|
| Zhao et al., 2013 [26] | 165 | Gastrectomy and chemotherapy; immunotherapy group: additional CIK cell therapy | Improved 5-yr PFS and OS in immunotherapy group; within the immunotherapy group, the frequency of CIK cell therapy, clinical stage, and follow-up therapy were the most important factors for PFS and OS | CIK cell therapy can prevent recurrence and improve survival in combination with gastrectomy and chemotherapy |
|
